文献速递糖尿病肥胖与代谢综合征

2型糖尿病中的痴呆:风险因素、疾病过程与全生命周期预防机会

Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.
PubMed 文献 · Diabetologia · 2026-07-13

2型糖尿病患者痴呆风险比非糖尿病人群高60-70%,随着老年糖尿病患者增多,预防痴呆日益重要。文章提出概率模型,认为2型糖尿病改变痴呆相关病理的发生概率及下游后果,预防应贯穿全生命周期并采取整体策略,降糖药(如GLP-1RA、SGLT2i)及多重心血管风险管理可能最有效。

要点

  • 2型糖尿病患者痴呆风险较非糖尿病人群高60-70%。
  • 2型糖尿病与痴呆关系宜用概率模型理解,涉及多重痴呆相关病理。
  • 预防应全生命周期整体降低风险因素暴露,而非针对单一因素。

核心结论

  • 2型糖尿病与痴呆的关系可通过概率模型理解,糖尿病改变痴呆相关病理的发生概率及下游后果。
  • 预防痴呆的机会贯穿全生命周期,需整体降低风险因素累积暴露而非针对单一因素。
  • 除预防2型糖尿病本身外,具有降糖外效应的药物(如GLP-1RA、SGLT2i)联合传统多重心血管风险管理可能最有效降低痴呆超额风险。

研究设计与样本

  • 本文为综述,基于PubMed来源,讨论2型糖尿病中痴呆的风险因素、疾病过程与预防机会。

主要发现

  • 2型糖尿病患者痴呆风险比非糖尿病人群高60-70%。
  • 尚未发现糖尿病特异性导致痴呆的病理。
  • 2型糖尿病改变痴呆相关病理的发生概率及其下游后果。

关键数值与推荐

  • 2型糖尿病患者痴呆风险较非糖尿病人群高60-70%。
  • 具有降糖外效应的药物包括多激素受体调节剂如GLP-1RA和SGLT2i。

临床怎么用

  • 对2型糖尿病患者应全生命周期整体管理痴呆风险因素,而非仅控制血糖。
  • 可考虑使用具有降糖外效应的药物(如GLP-1RA、SGLT2i)并结合多重心血管风险管理以降低痴呆风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with type 2 diabetes have a 60-70% higher risk of developing dementia than those without diabetes. Given the increasing number of older people living with diabetes, preventing dementia in this population is becoming increasingly important. However, dementia in individuals with type 2 diabetes is not a single entity and no diabetes-specific pathologies contributing to dementia have been identified yet. Here, we suggest that the relation between type 2 diabetes and dementia may be best understood through a probabilistic model that considers the context in which type 2 diabetes develops and the involvement of multiple dementia-related pathologies. Within this model, type 2 diabetes alters both the probability of dementia-related pathologies occurring and their downstream consequences. Opportunities for prevention of dementia evolve across the lifespan and comprise reducing cumulative exposures to dementia risk factors through a holistic approach rather than through targeting a single factor. Accordingly, beyond preventing type 2 diabetes itself, glucose-lowering medications with effects beyond glycaemic management (e.g. multihormone receptor modulators, such as glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors), alongside traditional multi-domain cardiovascular risk management, may be most effective at lowering excess dementia risk in individuals with type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. de Leijer JF, Biessels GJ, Visseren FLJ, et al. Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan. Diabetologia. 2026. PMID: 42440082. doi:10.1007/s00125-026-06795-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。